Please select the option that best describes you:
Is there any role for PARPi maintenance in BRCA-/HRD- patients after response to front line chemotherapy +/- bevacizumab?
Answer from: at Community Practice
This is a more complex question, and relies on a conversation with the patient and shared decision making. Unfortunately, the benefit seen with PARPi maintenance in BRCA-/HRD- patients was limited (PRIMA 8.1 vs. 5.4 months; PAOLA-1 16.9 vs. 16 months). I am also sensitive to implications of incorpor...
Sign in or Register to read more
Answer from: at Academic Institution
There is a role for monotherapy niraparib with an HR that approximates a 30% reduction in the hazard of risk of progression or death. (PRIMA trial, NEJM 2019)